Spotlight – What's next in Nash
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
Spotlight - Biotech tries everything it can in Nash
The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
Catalysts ahead for the smaller players
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
89bio’s home run fails to excite
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.
AASLD 2020 – Nash updates from Novo and Inventiva in focus
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Akero continues to pull ahead of Nash rivals
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.
